📰 Planegg News
Page 29 - Planegg News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Planegg. Real-time updates on events, politics, business and more.
April 16, 2023
Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary
April 16, 2023
16.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix) 16.04.2023 / ...
April 16, 2023
- Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 ... | June 19, 2023
April 14, 2023
Should You Buy or Sell MorphoSys Stock? Get The Latest MOR Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
April 4, 2023
EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023... | April 4, 2023
April 4, 2023
Morphosys is making faster progress than expected with research on its hopeful drug Pelabresib. Key results from the pivotal Phase 3 trial of its drug for the rare bone marrow cancer myelofibrosis... | April 4, 2023
April 4, 2023
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germa...
April 4, 2023
04.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CEST The issuer is solely responsible ...
March 24, 2023
EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (IS...
March 24, 2023
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6) 24.03.2023 / 17:00 CET/CESTThe issuer is solely responsible for the content of this announcement.NOT FOR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT I...